Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies

AIMS/INTRODUCTION: We evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum potassium elevation in Japanese patients with diabetic kidney disease. MATERIALS AND METHODS: We carried out a prespecified subanalysis of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shikata, Kenichi, Ito, Sadayoshi, Kashihara, Naoki, Nangaku, Masaomi, Wada, Takashi, Okuda, Yasuyuki, Sawanobori, Tomoko, Sugimoto, Kotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248426/
https://www.ncbi.nlm.nih.gov/pubmed/35199478
http://dx.doi.org/10.1111/jdi.13778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248426/
https://www.ncbi.nlm.nih.gov/pubmed/35199478
http://dx.doi.org/10.1111/jdi.13778

Ejemplares similares